Bevacizumab (anti-VEGF antibody) and pembrolizumab (anti-PD1 antibody) were approved in progressive and metastatic cervical cancers (50), and were also evaluated in SCCA, as well as other anti-PD1 antibodies (nivolumab, retifanlimab) (51), and showed a promising result in a subgroup of patients (52–54). The gene discussed is VEGFA; the disease is cervical carcinoma.